文献速递乳腺外科围术期管理与 ERAS

乳腺癌新辅助治疗后低体积淋巴结转移的腋窝清扫:AXSANA多中心队列研究

Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.
PubMed 文献 · Br J Surg · 2025-01-01

AXSANA前瞻性多中心队列研究纳入新辅助化疗后临床淋巴结转阴、因前哨淋巴结或目标淋巴结低体积转移(ITC或微转移)行完成性腋窝淋巴结清扫的患者,评估清扫后N分期升级情况。结果显示部分患者N分期升级,但均未获乳房pCR,升级未影响新辅助后治疗决策。

要点

  • 新辅助化疗后SLN/TLN低体积转移患者,cALND可发现额外淋巴结受累。
  • N分期升级者均无乳房pCR,故未改变新辅助后全身治疗决策。
  • cALND不应仅以诊断为目的用于此类低体积淋巴结转移患者。

核心结论

  • 尽管cALND在SLN/TLN低体积病变中可发现额外淋巴结受累,但未提供对新辅助后全身治疗调整有临床意义的信息,不应仅以诊断为目的鼓励cALND。

研究设计与样本

  • 前瞻性、国际、多中心AXSANA队列研究,2020年6月至2024年3月招募5329例患者,其中2194例计划行SLNB、TAD或TLNB。
  • 纳入新辅助化疗后临床淋巴结状态由阳性转为阴性、因SLN/TLN低体积转移而行cALND的患者。

主要发现

  • 16例ypN0i+(SLN/TLN)患者中,1例经cALND升级为ypN1a。
  • 71例ypN1mi(SLN/TLN)患者中,5例升级为ypN2,1例升级为ypN3。
  • 上述N分期升级患者均无乳房pCR,故N分期升级对新辅助后治疗决策无影响。

临床怎么用

  • 新辅助化疗后SLN/TLN低体积转移(ITC或微转移)患者,cALND的诊断价值有限,不应仅以明确N分期为目的常规实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Completion axillary lymph node dissection (cALND) is often recommended for patients with isolated tumour cells (ITCs) or micrometastases in the sentinel lymph node (SLN) or target lymph node (TLN) to assess the definite nodal tumour burden after neoadjuvant chemotherapy (NACT). The aim of this study was to investigate the upgrade of N stage by cALND in patients with low-volume metastases in the SLN/TLN after NACT from the prospective, international, multicentre AXSANA cohort study. METHODS: NACT-treated patients that converted from a positive to a negative clinical lymph node status and underwent cALND based on low-volume SLN/TLN involvement were included. The association between the final N stage, the pathological tumour response in the breast, and the clinical impact of cALND on post-NACT treatment decisions was determined. RESULTS: Among 5329 patients recruited between June 2020 and March 2024, 2194 were scheduled for SLN biopsy (SLNB), targeted axillary dissection (TAD), or TLN biopsy (TLNB). Among 16 patients with ypN0i+(SLN/TLN), one patient was upgraded to ypN1a by cALND, while five of the 71 patients with ypN1mi(SLN/TLN) were upstaged to ypN2 and one of the 71 patients with ypN1mi(SLN/TLN) was upstaged to ypN3. None of these patients had a pCR in the breast and thus nodal upstaging had no impact on post-NACT treatment decisions. CONCLUSION: Despite substantial additional nodal involvement in low-volume SLN/TLN disease, cALND does not provide clinically meaningful information for post-NACT systemic treatment modifications and should not be encouraged for diagnostic purposes alone.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Kühn T, Banys-Paluchowski M, Ditsch N, et al. Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study. Br J Surg. 2025. PMID: 40966675. doi:10.1093/bjs/znaf180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。